17. Multiple system atrophy Clinical trials / Disease details
Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04165486 (ClinicalTrials.gov) | July 7, 2020 | 14/11/2019 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered to Adults With Multiple System Atrophy | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered Intrathecally to Adults With Multiple System Atrophy | Multiple System Atrophy | Drug: BIIB101;Drug: Placebo | Biogen | NULL | Active, not recruiting | 40 Years | 70 Years | All | 34 | Phase 1 | Austria;France;Germany;Portugal;United Kingdom |